派林生物(000403) - 2017 Q3 - 季度财报

Financial Performance - Operating revenue for the current period was CNY 192,949,099.27, representing a 36.58% increase year-on-year[8] - Net profit attributable to shareholders decreased by 13.28% to CNY 14,088,031.71 compared to the same period last year[8] - Net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 14,053,478.44, a decrease of 9.90% year-on-year[8] - Basic earnings per share decreased by 16.67% to CNY 0.05[8] - The weighted average return on net assets was 2.28%, a decrease of 0.91% compared to the same period last year[8] Assets and Liabilities - Total assets increased by 4.88% to CNY 1,303,941,109.11 compared to the end of the previous year[8] - Net assets attributable to shareholders increased by 10.58% to CNY 613,028,025.39 compared to the end of the previous year[8] - Cash and cash equivalents decreased by 44.61% compared to the beginning of the year, mainly due to reduced cash settlement from Guangdong Shuanglin Biopharmaceutical Co., Ltd.[16] - Accounts receivable increased by 5428.15% compared to the beginning of the year, primarily due to increased sales receivables from Guangdong Shuanglin Biopharmaceutical Co., Ltd.[16] - Long-term borrowings decreased by 100% compared to the beginning of the year, as Guangdong Shuanglin Biopharmaceutical Co., Ltd. repaid part of its bank loans.[16] - Special payables increased by 159.14% compared to the beginning of the year, mainly due to government support funds received by subsidiary Guangdong Puaosi Biotechnology Co., Ltd.[16] - The company reported a significant increase in expected liabilities by 168.21% compared to the beginning of the year, mainly due to provisions for pending litigation claims.[16] Cash Flow - The net cash flow from operating activities was CNY -23,785,160.97, a decrease of 152.02% compared to the same period last year[8] - Net cash flow from operating activities decreased by 152.02% compared to the same period last year, mainly due to reduced cash settlements and increased payments for goods and employee salaries from Guangdong Shuanglin Biopharmaceutical Co., Ltd.[16] - The net increase in cash and cash equivalents decreased by 10768.33% compared to the same period last year, primarily due to reduced cash settlements and increased payments for goods and employee salaries.[18] Shareholder Information - The total number of shareholders at the end of the reporting period was 16,182[12] - The largest shareholder, Zhixing Group Co., Ltd., holds 22.61% of the shares, with 61,621,064 shares frozen[12] Other Information - Sales expenses increased by 196.16% compared to the same period last year, primarily due to changes in sales policies and increased academic promotion expenses at Guangdong Shuanglin Biopharmaceutical Co., Ltd.[16] - The company's net profit increased, leading to an increase in undistributed profits by 54.77% compared to the beginning of the year.[16] - The company has not conducted any significant asset restructuring during the reporting period, and there are no overdue commitments from major shareholders or related parties.[20][26]